Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 52

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 52
---
 in our information technology systems, our efforts may not be successful. Further, we may experience
delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Any failure to prevent
or mitigate security incidents or improper access to, use of, or disclosure of our clinical data or patients’ personal data could
result in significant liability under state, federal, and international law and may cause a material adverse impact to our reputation,
affect our ability to conduct our clinical trials and potentially disrupt our business.

Applicable data protection
laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security incidents. Such disclosures
are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third
party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may also experience
adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties,
audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including
personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund
diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.

Our contracts may not contain
limitations of liability, and even where they do, there can be no assurance that the limitations of liability in our contracts are sufficient
to protect us from liabilities, damages, or claims related to our data privacy and security obligations.

We cannot be sure that our
insurance coverage will be adequate or sufficient to protect us from or adequately mitigate liabilities arising out of our privacy and
security practices, or that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage
will pay future claims.

Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to
review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire
and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times